Harmonizing antibiotic regimens with renal replacement therapy

References

• Barbar SD, Binquet C, Monchi M, et al. Impact on mortality of the timing of renal replacement therapy in patients with severe acute kidney injury in septic shock: the IDEAL-ICU study (initiation of dialysis early versus delayed in the intensive care unit): study protocol for a randomized controlled trial. Trials. 2014 July 7;15:270.
   PubMedGoogle Scholar
• Bagshaw SM, George C, Bellomo R, et al. Early acute kidney injury and sepsis: a multicentre evaluation. Crit Care. 2008;12(2):R47.
   PubMed Web of Science ®Google Scholar
• Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017 Mar;43(3):304–377.
   PubMed Web of Science ®Google Scholar
• Pistolesi V, Morabito S, Di Mario F, et al. A guide to understanding antimicrobial drug dosing in critically ill patients on renal replacement therapy. Antimicrob Agents Chemother. 2019 Aug;63(8). DOI:10.1128/AAC.00583-19
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Mueller BA. Antibiotic dosing in critically ill patients receiving CRRT: underdosing is overprevalent. Semin Dial. 2014 Sept–Oct;27(5):441–445.
   PubMed Web of Science ®Google Scholar
• Seyler L, Cotton F, Taccone FS, et al. Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care. 2011;15(3):R137.
   PubMed Web of Science ®Google Scholar
• Fu CF, Huang JD, Wang JT, et al. The ratio of pre-dialysis vancomycin trough serum concentration to minimum inhibitory concentration is associated with treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia. PLoS One. 2018;13(3):e0193585.
   PubMed Web of Science ®Google Scholar
• El Nekidy WS, El-Masri MM, Ghazi IM, et al. Factors predicting vancomycin therapy outcomes in hemodialysis outpatients and the role of the nephrology stewardship pharmacist. Hemodial Int. 2019 Oct;23(4):449–457.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Drusano GL, Zasowski E, et al. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis. 2014 Sept 1;59(5):666–675.
   PubMed Web of Science ®Google Scholar
• Kullar R, Davis SL, Levine DP, et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011 Apr 15;52(8):975–981.
   PubMed Web of Science ®Google Scholar
• El Nekidy WS, El-Masri MM, Umstead GS, et al. Predicting maintenance doses of vancomycin for hospitalized patients undergoing hemodialysis. Can J Hosp Pharm. 2016 Sept–Oct;69(5):341–347.
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus aureus infections: a revised consensus guideline and review by the American society of health-system pharmacists, the infectious diseases society of America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists. Am J Health Syst Pharm. 2020 Mar 19. pii: zxaa036. DOI: 10.1093/ajhp/zxaa036. [Epub ahead of print].
   PubMedGoogle Scholar
• Drusano GL. Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol. 2004 Apr;2(4):289–300.
   PubMed Web of Science ®Google Scholar
• Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl. 1990;74:63–70.
   PubMedGoogle Scholar
• Clark WR, Mueller BA, Kraus MA, et al. Extracorporeal therapy requirements for patients with acute renal failure. J Am Soc Nephrol. 1997 May;8(5):804–812.
   PubMed Web of Science ®Google Scholar
• Sowinski KM, Magner SJ, Lucksiri A, et al. Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clin J Am Soc Nephrol. 2008 Mar;3(2):355–361.
   PubMed Web of Science ®Google Scholar
• Eschenauer GA, Lam SW, Mueller BA. Dose timing of aminoglycosides in hemodialysis patients: a pharmacology view. Semin Dial. 2016 May;29(3):204–213.
   PubMed Web of Science ®Google Scholar
• Edrees F, Li T, Vijayan A. Prolonged intermittent renal replacement therapy. Adv Chronic Kidney Dis. 2016 May;23(3):195–202.
   PubMed Web of Science ®Google Scholar
• Sinnollareddy MG, Roberts MS, Lipman J, et al. Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration. J Antimicrob Chemother. 2018 June 1;73(6):1647–1650.
   PubMed Web of Science ®Google Scholar
• Bue M, Sou T, Okkels ASL, et al. Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy. Int J Infect Dis. 2020 Jan 21;92:133–140.
   PubMed Web of Science ®Google Scholar
• Philpott CD, Droege CA, Droege ME, et al. Pharmacokinetics and pharmacodynamics of extended-infusion cefepime in critically ill patients receiving continuous renal replacement therapy: a prospective, open-label study. Pharmacotherapy. 2019 Nov;39(11):1066–1076.
   PubMed Web of Science ®Google Scholar
• Shotwell MS, Nesbitt R, Madonia PN, et al. Pharmacokinetics and pharmacodynamics of extended infusion versus short infusion piperacillin-tazobactam in critically ill patients undergoing CRRT. Clin J Am Soc Nephrol. 2016 Aug 8;11(8):1377–1383.
   PubMed Web of Science ®Google Scholar
• Adembri C, Fallani S, Cassetta MI, et al. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents. 2008 Feb;31(2):122–129.
   PubMed Web of Science ®Google Scholar
• Richter DC, Frey O, Rohr A, et al. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience. Infection. 2019 Dec;47(6):1001–1011.
   PubMed Web of Science ®Google Scholar
• Choi G, Gomersall CD, Tian Q, et al. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med. 2009 July;37(7):2268–2282.
   PubMed Web of Science ®Google Scholar
• Claure-Del Granado R, Macedo E, Chertow GM, et al. Effluent volume in continuous renal replacement therapy overestimates the delivered dose of dialysis. Clin J Am Soc Nephrol. 2011 Mar;6(3):467–475.
   PubMed Web of Science ®Google Scholar
• Vilay AM, Churchwell MD, Mueller BA. Clinical review: drug metabolism and nonrenal clearance in acute kidney injury. Crit Care. 2008;12(6):235.
   PubMed Web of Science ®Google Scholar
• Giles LJ, Jennings AC, Thomson AH, et al. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med. 2000 Mar;28(3):632–637.
   PubMed Web of Science ®Google Scholar
• Ververs TF, van Dijk A, Vinks SA, et al. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Crit Care Med. 2000 Oct;28(10):3412–3416.
   PubMed Web of Science ®Google Scholar
• Christensson BA, Nilsson-Ehle I, Hutchison M, et al. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 1992 July;36(7):1532–1537.
   PubMed Web of Science ®Google Scholar
• Veinstein A, Venisse N, Badin J, et al. Gentamicin in hemodialyzed critical care patients: early dialysis after administration of a high dose should be considered. Antimicrob Agents Chemother. 2013 Feb;57(2):977–982.
   PubMed Web of Science ®Google Scholar
• Venisse N, Dupuis A, Badin J, et al. Efficacy and safety of high-dose gentamicin re-dosing in ICU patients receiving haemodialysis. J Antimicrob Chemother. 2015 Jan;70(1):308–310.
   PubMed Web of Science ®Google Scholar
• Jang SM, Gharibian KN, Lewis SJ, et al. A monte carlo simulation approach for beta-lactam dosing in critically ill patients receiving prolonged intermittent renal replacement therapy. J Clin Pharmacol. 2018 Oct;58(10):1254–1265.
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Chaijamorn W, Shaw AR, et al. In silico trials using Monte Carlo simulation to evaluate ciprofloxacin and levofloxacin dosing in critically ill patients receiving prolonged intermittent renal replacement therapy. Ren Replace Ther. 2016;2:45.
   Google Scholar
• Gharibian KN, Mueller BA. Fluconazole dosing predictions in critically-ill patients receiving prolonged intermittent renal replacement therapy: a Monte Carlo simulation approach. Clin Nephrol. 2016 July;86(7):43–50.
   PubMedGoogle Scholar
• Lewis SJ, Kays MB, Mueller BA. Use of Monte Carlo simulations to determine optimal carbapenem dosing in critically ill patients receiving prolonged intermittent renal replacement therapy. J Clin Pharmacol. 2016 Oct;56(10):1277–1287.
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Mueller BA. Development of a vancomycin dosing approach for critically ill patients receiving hybrid hemodialysis using Monte Carlo simulation. SAGE Open Med. 2018;6:2050312118773257.
   Web of Science ®Google Scholar
• Burkhardt O, Joukhadar C, Traunmuller F, et al. Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis. J Antimicrob Chemother. 2008 Jan;61(1):224–225.
   PubMed Web of Science ®Google Scholar
• Swoboda S, Ober MC, Lichtenstern C, et al. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol. 2010 Mar;66(3):291–298.
   PubMed Web of Science ®Google Scholar
• .Scoville BA,Mueller BA. Medication dosing in critically ill patients with acute kidney injury treated with renal replacement therapy. Am J Kidney Dis. 2013;61(3):490-500.
   PubMed Web of Science ®Google Scholar
• Manley HJ, Bailie GR, McClaran ML, et al. Gentamicin pharmacokinetics during slow daily home hemodialysis. Kidney Int. 2003 Mar;63(3):1072–1078.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Field J, Visser A, et al. Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury. Antimicrob Agents Chemother. 2010 Sept;54(9):3635–3640.
   PubMed Web of Science ®Google Scholar
• Moriyama B, Henning SA, Neuhauser MM, et al. Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria. Ann Pharmacother. 2009 July;43(7):1324–1337.
   PubMed Web of Science ®Google Scholar
• Mariat C, Venet C, Jehl F, et al. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation. Crit Care. 2006 Feb;10(1):R26.
   PubMed Web of Science ®Google Scholar
• Tam VH, McKinnon PS, Akins RL, et al. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother. 2002 Sept;50(3):425–428.
   PubMed Web of Science ®Google Scholar
• Thurmann-Nielsen E, Walstad RA, Dahl K, et al. Ceftazidime in patients with impaired renal function. Studies on pharmacokinetics and nephrotoxicity. J Chemother. 1989 July;1(4 Suppl):534–535.
   PubMedGoogle Scholar
• Vu DH, Nguyen DA, Delattre IK, et al. Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: population pharmacokinetic modelling and simulations for improved dosing schemes. Int J Antimicrob Agents. 2019 Dec;54(6):702–708.
   PubMed Web of Science ®Google Scholar
• Economou CJP, Kielstein JT, Czock D, et al. Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy. Int J Antimicrob Agents. 2018 Aug;52(2):151–157.
   PubMed Web of Science ®Google Scholar
• Jang SM, Pai MP, Shaw AR, et al. Antibiotic exposure profiles in trials comparing intensity of continuous renal replacement therapy. Crit Care Med. 2019 Nov;47(11):e863–e871.
   PubMed Web of Science ®Google Scholar
• Mueller BA, Smoyer WE. Challenges in developing evidence-based drug dosing guidelines for adults and children receiving renal replacement therapy. Clin Pharmacol Ther. 2009 Nov;86(5):479–482.
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Mueller BA. Antibiotic dosing in patients with acute kidney injury: “enough but not too much”. J Intensive Care Med. 2016 Mar;31(3):164–176.
   PubMed Web of Science ®Google Scholar
• Jamal JA, Mueller BA, Choi GY, et al. How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy? Diagn Microbiol Infect Dis. 2015 May;82(1):92–103.
   PubMed Web of Science ®Google Scholar